Anticoagulant drugs antagonize coagulation and are used to prevent or cure (recurrent)
venous thromboembolism (VTE). Drugs to prevent clotting have been used for more than a …

The complete picture of the outcomes of venous thromboembolism (VTE) care consists of
conventional binary clinical outcomes (death, recurrent VTE, and bleeding), patient-centered …

Aims To systematically assess late outcomes of acute pulmonary embolism (PE) and to
investigate the clinical implications of post-PE impairment (PPEI) fulfilling prospectively …

Preliminary data and clinical experience have suggested an increased risk of abnormal
uterine bleeding (AUB) in women of reproductive age treated with anticoagulants, but solid …

Background Cardiopulmonary exercise testing (CPET) may provide prognostically valuable
information during follow-up after pulmonary embolism (PE). Our objective was to …

Patients with acute venous thromboembolism (VTE) require anticoagulant therapy to prevent
recurrent VTE and death, which exposes them to an inherent increased risk of bleeding …

Background As mortality from pulmonary embolism (PE) decreases, the personal and
societal costs among survivors are receiving increasing attention. Detailing this burden …

Background Diagnostic rates and risk factors for the subsequent development of chronic
thromboembolic pulmonary hypertension (CTEPH) following pulmonary embolism (PE) are …

A broad spectrum of long-term sequelae may be present in venous thromboembolism (VTE)
survivors, affecting their quality of life and functioning. To monitor recovery and improve the …

Survivors of acute pulmonary embolism (PE) are at risk of developing persistent, sometimes
disabling symptoms of dyspnea and/or functional limitations despite adequate anticoagulant …